Please assess the completion status of the following clinical trial:

Trial Title: Subunit Vaccine Against Herpes Zoster in RA Patients Treated With JAK-inhibitors (VACCIMIL-ZOSTER)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~age\>18 years RA diagnosis RA patients treated with JAK-inhibitors as monotherapy or in combination with MTX and/or other DMARDs/prednisolone for at least 3 months (group1) regulary follow up at the rheumatology departmenet~Exclusion Criteria:~* pregnancy~* breastfeeding~* allergi against some of compnents in the vaccine~* ongoing infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- RA patients on JAK inhibitors (Type: ACTIVE_COMPARATOR): RA patients treated with JAK inhibitors as a monotherapy or in combination with methotrexate/other DMARDs/prednisone for at least 3 months will receive two doses of Shingrix vaccine administrated with at least 2 months apart
- healthy controls (Type: ACTIVE_COMPARATOR): healthy individuals without any rheumatic disease or not treated with any immunosupressive drug for any other condition will receive two doses of Shingrix vaccine administrated with at least 2 months apart

Based on this trial design, predict the completion outcome and termination type (if applicable).